Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...

Eli Lilly now offers higher doses of its weight-loss drug Zepbound in vial form at a discount to the injector pen versions.

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

MarketWatch was able to verify Zeng's claims via videos and was also able to order delivery of Ozempic to an address in China. The price was 798 yuan ($108) for a one-month supply that is injected ...

Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

Many employers and insurers are scaling back coverage of Wegovy and Zepbound, and a key government program, Medicare, doesn’t ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE: NVO) stands against the other ...